Randomized, Open-label, Single Dose, Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics of DW1029M 300 mg, 600 mg and 1200 mg After Oral Administration in Healthy Male Volunteer
Latest Information Update: 18 Sep 2019
At a glance
- Drugs DW 1029M (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacokinetics
- Sponsors Dong Wha Pharmaceutical
- 16 Jan 2014 New source identified and integrated (Clinical Research Information Service(CriS) - Republic of Korea)
- 15 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov
- 18 Dec 2013 Planned End Date changed from 1 Mar 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.